Xencor Inc
F:XE9
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.65
19.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Xencor Inc
NASDAQ:XNCR
|
901.8m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
380.6B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.3B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.5B USD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Xencor Inc
Glance View
Xencor Inc. is an innovative biotechnology company, distinguished by its commitment to harnessing the power of engineered monoclonal antibodies to fight complex diseases, especially within the realms of cancer and autoimmune disorders. Founded in 1997 and headquartered in Monrovia, California, Xencor relies on its proprietary XmAb technology platform – a sophisticated approach that enhances the structure and function of monoclonal antibodies to improve therapeutic performance. This technology enables Xencor to develop antibodies that are more potent, stable, and precise, ultimately driving their efficacy in targeting particular cellular mechanisms associated with disease progression while minimizing side effects. By focusing on core biological processes, Xencor leverages its platform to innovate new therapies that offer significant improvements over existing treatments, making it a nimble player in the competitive biotech landscape. Xencor's business model hinges on a dual strategy of internal drug development and strategic collaborations. Internally, Xencor is advancing a robust pipeline of drug candidates aimed at addressing various unmet medical needs, many of which are in various stages of clinical trials. These in-house projects are crucial for establishing the company's reputation as a leader in antibody engineering. In parallel, Xencor partners with larger pharmaceutical companies, licensing its XmAb technology and co-developing drugs—a model that provides a steady revenue stream from milestone payments, royalties, and research support. This hybrid approach not only diversifies Xencor's risk portfolio but also enhances its financial resilience, enabling a sustainable path to growth amidst the volatile biotech sector. Through this innovative framework, Xencor is poised to continue its influence in the biopharmaceutical industry, driven by a mission to bring transformative therapies to patients in need.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Xencor Inc is -71.6%, which is above its 3-year median of -121.6%.
Over the last 3 years, Xencor Inc’s Operating Margin has decreased from 17.5% to -71.6%. During this period, it reached a low of -255.3% on Sep 30, 2024 and a high of 17.5% on Aug 30, 2022.